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Abstract
Objectives: To demonstrate how individual participant data (IPD) meta-analyses have impacted directly on the design and conduct of
trials and highlight other advantages IPD might offer.
Study Design and Setting: Potential examples of the impact of IPD meta-analyses on trials were identified at an international work-
shop, attended by individuals with experience in the conduct of IPD meta-analyses and knowledge of trials in their respective clinical areas.
Experts in the field who did not attend were asked to provide any further examples. We then examined relevant trial protocols, publications,
and Web sites to verify the impacts of the IPD meta-analyses. A subgroup of workshop attendees sought further examples and identified
other aspects of trial design and conduct that may inform IPD meta-analyses.
Results: We identified 52 examples of IPD meta-analyses thought to have had a direct impact on the design or conduct of trials. After
screening relevant trial protocols and publications, we identified 28 instances where IPD meta-analyses had clearly impacted on trials. They
have influenced the selection of comparators and participants, sample size calculations, analysis and interpretation of subsequent trials, and
the conduct and analysis of ongoing trials, sometimes in ways that would not possible with systematic reviews of aggregate data. We iden-
tified additional potential ways that IPD meta-analyses could be used to influence trials.
Conclusions: IPD meta-analysis could be better used to inform the design, conduct, analysis, and interpretation of trials. Crown
Copyright  2015 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
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1. Introduction
Systematic reviews are recognized as the optimal way to
resolve or confirm uncertainty about the effects of interven-
tions, both informing clinical practice and providing the sci-
entific and ethical justification for the design of new trials
[1]. However, empirical evidence suggests that they are still
used infrequently to explain the rationale for [2e4] or
directly influence the design of trials [3,4]. Systematic re-
views can also be used to take account of external evidence
that accumulates during the conduct of a trial, thereby
ensuring that participant recruitment and any protocol
amendments are informed by the accumulating external ev-
idence; however, it is not clear how often this actually hap-
pens. When a trial is completed, systematic reviews can also
help place the results in the context of the results of other
related trials, but this is far from standard practice [3,5,6].
Most commonly, systematic reviews are based on aggre-
gate data extracted from publications or obtained from trial
investigators, which can limit the availability and quality of
such data. Furthermore, the range of analyses possible with
aggregate data is limited, and they may lack power. Instead,
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What is new?
 Systematic reviews and meta-analyses based on
aggregate data can inform subsequent clinical tri-
als, but empirical evidence of this happening is
limited.
 Systematic reviews and meta-analyses based on
IPD are international collaborative projects that
often provide more detailed and reliable results
and so have greater potential to inform trials.
 To our knowledge, this is the first attempt to
explore the impact of IPD meta-analyses on
ongoing and subsequent trials.
 We identified examples of IPD meta-analyses hav-
ing a direct impact on trial design, conduct, anal-
ysis, and interpretation, sometimes in ways that
would not be possible with aggregate data.
 IPD meta-analysis could be better used to inform
additional aspects of design and conduct.
systematic reviews and meta-analyses that involve individ-
ual participant data (usually called IPD meta-analyses) tend
to be larger scale, international projects in which re-
searchers collaborate to collect and analyze the original
data from all the studies relevant to the review question
[7e9]. A well-conducted IPD meta-analysis [10] can bring
about substantial improvements to the quantity and quality
of the data, for example, by including more eligible trials
and participants, and to the analysis, by allowing the inves-
tigation of whether treatment effects vary by participant
characteristics [8,9]. Thus, they often provide more detailed
and reliable results and a greater depth of understanding
than is possible from aggregate data. This has led to them
being coined the ‘‘gold standard’’ of systematic review
[11]. Collated IPD also represents a unique resource for
secondary hypothesis testing and exploratory analyses,
which can provide further clinical insight. Thus, IPD
meta-analyses have the potential to inform the design,
conduct, analysis, and interpretation of subsequent trials
in ways that are IPD specific, as well as in ways that would
also be possible aggregate data. This article aims to provide
verified examples of both. Given that IPD meta-analyses
can take longer and be more resource intensive than stan-
dard systematic reviews based on aggregate data, we also
want to highlight how IPD meta-analyses might be better
used to inform ongoing or new trials.
2. Methods
Funders of randomized trials often require that relevant
systematic reviews are cited and used in the trial funding
application, and this direct linkage has allowed researchers
to use cohorts of such applications to assess the impact of
aggregate data systematic reviews on trial design and
conduct [4]. It would not be possible to define a similar
cohort of trials and trace the impact of IPD meta-analyses
on these, as IPD meta-analyses are not a requirement for
trial funding and remain relatively few in number.
Therefore, rather than comprehensively identifying the
effects of IPD meta-analyses on trials, we aim to provide
a range of illustrative examples. Initially, we sought exam-
ples at an international workshop of 31 members of the
Cochrane IPD Meta-analysis Methods Group, which took
place in London in September 2012. Not only did the at-
tendees have considerable experience in the conduct of
IPD meta-analyses, but also actively collaborate with tria-
lists as part of the IPD approach and have valuable knowl-
edge of trials in their respective clinical areas. In March
2015, we also surveyed the entire membership of the
Methods Group to solicit further examples. Two authors
(J.F.T. and S.B.) screened relevant trial protocols, publica-
tions, and Web sites to verify those IPD meta-analyses that
were used to support trial design and conduct (Boxes 1e3
and Table 1). A subgroup of workshop attendees (the au-
thors) sought further examples of impact from their own
experience and identified aspects of trial design and
conduct that might better informed by IPD meta-analyses.
3. Results
We identified 52 IPD meta-analyses thought to have had
direct impacts on the design and conduct of trials. On
further investigation, we could find no evidence of a link
between 24 IPD meta-analyses and trials but that is not to
say that such a link does not exist. For five of these exam-
ples, we suspect that it was too soon after the publication of
the IPD meta-analysis for a trial to have credited it. There-
fore, we found 28 IPD meta-analyses giving 29 instances
where the trial protocol, publication, or Web site explicitly
described how an IPD meta-analysis had influenced the
trial. Sometimes more than one IPD meta-analysis contrib-
uted to an impact or more than one impact was derived
from a single IPD meta-analysis. In 19 cases, these impacts
would only be possible with IPD, either because the results
or other aspects were IPD specific (Boxes 1e3, Table 1).
For the remaining 10, the impacts we identified might also
have been possible with an equivalent aggregate data meta-
analyses (Box 1, Table 1). This cohort of examples has also
helped highlight the ways in which IPD meta-analyses
might be underused in trial design and conduct.
3.1. Impact on trial design
3.1.1. Choosing comparators
Systematic reviews and meta-analyses based on aggre-
gate data have the potential to influence the choice of
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comparators in a subsequent trial, and there is already some
evidence of this [4]. We found too that IPD meta-analyses
showing a clear, robust, and clinically relevant effect of an
intervention have been used to justify use of the interven-
tion as a control group comparator in subsequent random-
ized trials (breast cancer 1, Table 1). Even when results
of an IPD meta-analysis were less definitive but suggested
that an intervention might be beneficial, we saw that this
can maintain or generate interest in particular therapeutic
comparisons, giving the impetus both for ongoing trials to
continue and for confirmatory or trials to be conducted
(NSCLC 1, Table 1). Instead, an IPD meta-analysis that
fails to show any benefit or shows that a therapy is harmful
could provide the rationale for discontinuing its further
investigation and for the current standard therapy to remain
as a control against which emerging therapies should be
compared, but we did not find evidence of the overall re-
sults of a meta-analysis being used in this way. Although
we suspect that this is because it is easier to justify main-
taining the status quo, without explicit reference to a sys-
tematic review, ideally the current evidence should be cited.
3.1.2. Promoting consensus and collaboration
The collaborative group needed to conduct an IPD meta-
analysis often includes those investigators who have supplied
their trial data, and we have found that this can facilitate
Box 1 Impact on trial design: choice of comparators, and reaching consensus and collaboration on the next trial
The individual participant data (IPD) meta-analyses
 Five meta-analyses comparing the effects of different types of chemotherapy for advanced ovarian cancer [12].
 One related meta-analysis comparing CAP (cyclophosphamide, doxorubicin, and cisplatin) with CP (cyclophospha-
mide and cisplatin) chemotherapy [13].
 Together included |50 trials and |10,000 women.
 Provided the first comprehensive synthesis of the effects of chemotherapy for advanced ovarian cancer.
The pertinent results
 Platinum-based chemotherapy better than nonplatinum chemotherapy [12].
 Platinum-based combination chemotherapy better than single-agent platinum-based chemotherapy [12].
 No clear difference between the effects of carboplatin and cisplatin when used as single agents or when substituted
for one another in combination regimens [12].
 CAP better than CP but dose of cisplatin in CAP regimen suboptimal because of toxicity [13].
Impact on new trials
(1) Informed choice of comparators in new trial.
 International Collaborative Ovarian Neoplasm 2 trial (ICON2) compared CAP with optimal dose carboplatin [14];
the latter being less toxic than cisplatin.
 In its time, ICON2 was the largest trial to be conducted in ovarian cancer and it showed definitely that carboplatin
was an effective but less toxic treatment than CAP for women with advanced ovarian cancer.
 Carboplatin was the control group comparator in the subsequent ICON3 trial [15].
 Impact may have been possible using aggregate data.
(2) Collaboration
 Large-scale collaboration was needed to achieve a trial of sufficient size and was formed from the meta-analyses
collaborative groups.
 A total of 1,526 patients in ICON2 were recruited by 132 centers in nine countries.
 Collaborations and strategic planning of ovarian cancer trials (ICON 1e8) have continued long after the original
meta-analysis.
 Impact only possible because of the individual participant data approach.
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consensus being reached on the design of subsequent trials
(Box 1). It is common practice to bring together such a group
of individuals, from different clinical specialties and disci-
plines to discuss the preliminary results of an IPD meta-
analysis and their implications. As this is often in advance
of formal presentation or publication of the results, it can also
help speed up the design and launch of a new trial (Box 1) or
even refine the design of one still in development (soft tissue
sarcoma 1, Table 1). Moreover, a group of trialists are well
placed to judge how a new trial might be achieved and by
whom. In one example, where large-scale international
collaboration was needed to achieve a trial of sufficient size
(to detect a small predicted treatment effect), it was drawn
from the meta-analyses collaborative groups (Box 1); an
advantage likely restricted to the IPD approach.
3.1.3. Determining sample size
A new trial can draw on estimates of control group or
baseline risk provided by a meta-analysis to give a good
indication of the approximate effect size to target in trials
of new or confirmatory comparisons. Examples of these
sorts of impact are evident for both IPD (NSCLC 1, cervix
I, Table 1) and aggregate data reviews [4]. It would be
possible to interrogate the IPD further to provide estimates
of baseline risk for particular types of participant, such as
those who might be expected to benefit most from a new
therapy, thereby helping to refine or improve the reliability
of sample size calculations. IPD could also be used to
inform predictions of trial duration and follow-up and
hence, resourcing, we did not find examples of IPD meta-
analyses being exploited to this extent.
3.1.4. Defining the population
Pooling IPD from multiple trials provides considerably
more power than any individual trial to investigate how
participant or disease characteristics interact with treatment
effects, and uniquely, the IPD also allow the relative influ-
ence of multiple trial and participant characteristics to be
considered simultaneously, which can help deal with con-
founding [53]. Not surprisingly then, IPD meta-analyses
showing interactions between treatment effects and partic-
ular participant or disease characteristics have been used to
Box 2 Impact on trial analysis and interpretation:
validated prognostic factor used to stratify
new trial analysis, which formed part of the
final report
The individual participant data (IPD) meta-
analysis
 Eleven acute stroke trials, 5,843 participants fitting
entry criteria [16] from the Virtual International
Stroke Archive (VISTA, www.gla.ac.uk).
Pertinent results
 Prognostic model developed and validated using
IPD.
 Provided the predicted probability of a poor
outcome at 6 months [16].
Impact on new trials
(1) Prognostic factor analysis informed trial analysis
stratification.
 Predicted probability of a poor outcome used to
stratify the analysis of IST-3 trial of thromboly-
sis vs. control.
 Larger benefit of thrombolysis was seen with
higher probability of a poor outcome [17].
 Impact only possible because individual partic-
ipant data were used.
Box 3 Impact on trial conduct: designed
prospective individual participant data
(IPD) meta-analysis of ongoing trials to
achieve power, encourage continued
recruitment, and inform trial analyses
The IPD meta-analysis
 Adjuvant vs. salvage radiotherapy after radical
prostatectomy for locally advanced prostate cancer.
 Three trials (RADICALS [ISRCTN40814031],
RAVES [NCT00860652], GETUG-17 [NCT00
667069]) and |2,000 patients
Impact on ongoing trials
(1) To achieve power for key outcomes
 Trials are recruiting slowly and the prognosis of
participants is better than expected, so a meta-
analysis will help achieve sufficient power to
detect an effect on survival.
 Impact only possible because of individual
participant data approach.
(2) Informing the conduct
 Used to justify and encourage continued recruit-
ment, follow-up, and funding of ongoing trials
[18].
(3) Informing the analysis
 Deciding on definition and analysis of interme-
diate outcomes.
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Table 1. Further examples of the impact of IPD meta-analyses on trial design, conduct, analysis, and interpretation
Example Description of IPD meta-analyses What was the impact? Impact IPD specific
Trial design
Breast cancer [1]  3 IPD meta-analyses comparing effects of
hormonal therapy vs. non or two durations
of this treatment for early breast cancer
[19].
 71 Trials and 80,273 patients.
 Informed choice of comparators in the
ATLAS trial [20,21].
 No
Nonesmall cell
lung cancer [1]
 4 IPD meta-analyses investigating effects
of adding chemotherapy to surgery; surgery
and radiotherapy; radiotherapy and
supportive care [22].
 52 Trials and 9,387 patients.
 Informed the choice of comparators in new
trials in locally advanced disease [23,24].
 Renewed enthusiasm for chemotherapy led
to collaborations on new trials from IPD
collaborative group [25e28].
 Control group survival and absolute survival
benefits used as the basis for sample size
calculation [27,28].
 No
 Yes
 No
Soft tissue
sarcoma [1]
 1 IPD meta-analysis investigating the
effects of adding doxorubicin-based
chemotherapy after local treatment [29].
 14 Trials and 1,568 patients.
 Subgroup results helped define population
in the RTOG 95-14 trial [30].
 Yes
Cervical cancer [1]  1 IPD meta-analysis investigating
concomitant chemoradiotherapy vs. the
same radiotherapy [31].
 18 Trials and 4,818 patients.
 IPD meta-analysis and another trial
together informed choice of comparators in
the OUTBACK trial (ANZGOG 0902/GOG-
0274/RTOG 1174).
 Control group survival used as the basis for
sample size calculation in the OUTBACK
trial.
 No
 No
Hypertension [1]  1 IPD meta-analysis investigating
antihypertensive drugs in very elderly
patients [32].
 7 Trials and 1,670 patients.
 Subgroup results helped define the popu-
lation in the HYVET trial [33,34].
 Yes
Hypertension [2]  1 IPD meta-analysis investigating the effect
of antihypertensive treatment in patients
having already suffered a stroke [35].
 9 Trials and 6,752 patients.
 Subgroup results helped define population
for the PROGRESS trial [36].
 Yes
Hypertension [3]  1 IPD meta-analysis investigating diuretic
vs. placebo-based treatment of
hypertension for diabetes [37].
 4 Trials and 18,097 patients.
 Subgroup results helped define population
for the ADVANCE trial [38,39].
 Yes
Head and neck [1]  1 IPD meta-analysis comparing
conventional radiotherapy vs. altered
fractionated radiotherapy for head and neck
cancer [40].
 15 Trials and 6,515 patients.
 Subgroup results helped define population
of GORTEC-ELAN-RT (NCT01864850)
trial.
 Yes
Small-cell lung
cancer [1]
 1 IPD meta-analysis comparing
prophylactic cranial irradiation (PCI) vs.
none in patients with small-cell lung cancer
[41].
 7 Trials and 987 patients.
 Informed choice of comparators in PCI 99-
01/EORTC 22003-08004/RTOG 0212/
IFCT 99-01 trial [42].
 No
Breast cancer [2]  1 IPD meta-analysis comparing
radiotherapy and other treatments vs. the
same other treatment with no radiotherapy
[43].
 40 RCTs and 19,582 patients.
 Informed choice of comparators in SU-
PREMO trial (ISRCTN 61145589).
 No
(Continued )
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justify focusing on particular subgroups or characteristics
in subsequent trials (e.g., hypertension 1 and head and neck
1, Table 1). Although being able to establish with confi-
dence that an effect is not modified by a participant or dis-
ease characteristics can reassure trialists that the
inclusion criteria should remain broad for the next trial,
we did not find evidence of IPD meta-analyses results be-
ing used in this way.
IPD collected for a meta-analysis also provide a resource
for assessing the prognostic effects of individual character-
istics or for defining risk groups based on multiple
prognostic factors. In particular, detailed IPD from multiple
studies offer the possibility to both generate and validate
prognostic models within the same meta-analysis or to vali-
date already established prognostic standards (Box 2),
which could be used to inform the stratified randomization
procedures in subsequent trials, although we have not found
any examples of this. As aggregate data meta-analyses usu-
ally cannot be used to determine appropriately prognostic
effects or interactions between treatment effects and indi-
vidual participant characteristics [54,55], we would not
expect them to affect trials in these ways.
Table 1. Continued
Example Description of IPD meta-analyses What was the impact? Impact IPD specific
Nonesmall cell
lung cancer [2]
 1 IPD meta-analysis of postoperative
radiotherapy vs. none [44].
 11 RCTs and 2,343 patients.
 Subgroup results helped define population
in the Lung ART trial (NCT00410683)
 Yes
Stroke [1]  Prospective IPD meta-analysis comparing
antidepressants vs. none in recovering
stroke patients.
 2 Trials and 4,600 patients (approx.).
 Prospective IPD meta-analysis led to com-
mon trial design of the two included trials
B Affinitydwww.affinitytrial.org
B FOCUSdwww.focustrial.org.uk
 Yes
Preterm neonates  Prospective IPD meta-analysis comparing
oxygen saturation given to extremely
premature babies [45].
 5 Trials and 5,000 patients (approx).
 Prospective IPD meta-analysis to achieve
power for key outcomes.
 Yes
Trial conduct
Colon cancer [1]  Prospective IPD meta-analysis comparing
adjuvant fluorouracil and folinic acid vs.
control for Dukes B and C colon cancer
[46].
 3 Trials and 1,493 patients.
 Prospective IPD meta-analysis used to
achieve power for key outcome.
 Yes
Stroke [1]  As above  Collaborative design of prospective IPD
meta-analysis study materials in the two
included trials.
 Yes
Nonesmall cell
lung cancer [3]
 1 IPD meta-analysis of postoperative
platinum-based chemotherapy vs. none for
NSCLC [47].
 2 Trials and 494 patients.
 Subgroup results used as rationale for trial
stopping (IFCT 0801, TASTE
(NCT00775385 [48,49].
 Yes
Preterm neonates  As above  Prospective IPD meta-analysis influenced
aspects of the individual trials, for example,
data collection and study materials.
 Yes
Trial analysis and interpretation
Soft tissue
sarcoma [2]
 IPD meta-analysis investigating the effects
of adding doxorubicin-based chemotherapy
after local treatment [29].
 14 Trials and 1,568 patients.
 EORTC 62931 trial report uses results of
meta-analysis and subsequent trials to
places trial results in context [50].
 No
Stroke [1]  As above  Prospective IPD meta-analysis influenced
planned analysis of two included trials.
 Yes
Bladder cancer  IPD meta-analysis of adjuvant chemo-
therapy vs. none in bladder [51].
 6 Trials and 491 patients.
 EORTC 30994 trial report [52] uses results
of IPD meta-analyses and subsequent
results to places trial results in context.
 No
Abbreviations: IPD, individual participant data; RCT, randomized controlled trial.
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3.1.5. Choosing outcomes
There is certainly evidence that aggregate data reviews
have helped inform the choice of outcomes in new trials
[4]. However, a major advantage of making such decisions
based on an IPD meta-analysis is that often it will include
data on more outcomes per trial and more complete infor-
mation on those outcomes, and therefore, results are less
likely to be skewed by the biases associated with selective
reporting of outcomes [56]. For example, when an IPD
meta-analysis establishes that benefits of treatments are
consistent across related outcomes, it can provide extra
reassurance that a certain intervention should be used in
subsequent trials (head and neck 1, NSCLC 1, Table 1).
In contrast, the identification of differential effects of an
intervention across related outcomes, with IPD, can give
a clearer picture of its mode of action and more specifically
inform trial design (head and neck 1, Table 1). As underre-
porting of harms of interventions is particularly prevalent in
RCTs [57], perhaps only an IPD meta-analysis including
comprehensive data on such outcomes and so properly
ascribing the risks of a therapy can properly inform this
aspect of the design of subsequent trials. Less obvious
perhaps is that the process of seeking data from multiple
trials for an IPD meta-analysis can highlight not only those
outcomes that were underreported, but also those that that
were not collected routinely, so providing evidence on
where there is room for improvement [31]. However, we
did not find examples of IPD meta-analyses being used to
inform these sorts of decisions in new trials.
Although aggregate data can be used to determine
whether the effects of an intervention on a proposed surro-
gate and final outcome are correlated, associations between
these outcomes using participant-level data are considered
necessary for proper surrogate validation [58]. Thus, data
from one or more IPD meta-analyses can be used as a
resource to identify reliable surrogate outcomes, as well
as those that are clearly unsuitable. In principle, this might
identify shorter-term surrogates with the potential to speed
up the evaluation of therapies in new trials. Alternatively,
finding a reliable surrogate outcome that is more practical
to measure could facilitate outcome data collection and
so improve data quality in subsequent trials. Although
IPD meta-analyses have been used to validate surrogate
outcomes [59,60], in our cohort, we did not find evidence
of trials adopting such surrogate outcomes on the basis of
these analyses. One possible explanation is that the treat-
ments investigated in the new trials are different to those
evaluated in prior meta-analysis, such that further valida-
tion would be necessary.
3.1.6. Defining and collecting outcome data
If outcomes have been defined and analyzed very differ-
ently in individual trials, it may be necessary to make as-
sumptions about their comparability or use standardized
effect measures in aggregate data meta-analysis, whereas
IPD offer the opportunity to translate varying outcome
definitions into an agreed common scale or to generate
standardized definitions from other data items [61]. Thus,
if an IPD meta-analysis can demonstrate effects of a ther-
apy based on such a common or standardized outcome defi-
nition, it provides trialists with both the rationale and
motivation for adopting a standard definition in future tri-
als. Moreover, the process of collecting IPD can reveal out-
comes or outcome definitions that generate better or poorer
quality data, which could also help optimize how data are
defined and collected in the next generation of trials. To
our knowledge, however, these advantages of IPD have
not been explicitly described in the design of RCTs.
For time-to-event outcomes, a major advantage of col-
lecting IPD is the ability to obtain additional follow-up
from investigators, sometimes substantially beyond the
aggregate data results reported in trial publications.
Although the primary aim is to provide more events and
greater power for the analysis, importantly, this practice
can help reveal the pattern of events over time. In partic-
ular, any benefits or harms of interventions that take a long
time to accrue, such as late side effects of treatment or late
recurrence of disease, can become apparent. We did find an
example, where the IPD meta-analysis highlighted the need
to collect long-term outcome data in subsequent trials, as
well as informing the appropriate duration of data collec-
tion (breast cancer 1 Table 1).
3.2. Impacts on trial conduct
3.2.1. Informing the conduct of ongoing trials
For trials that are ongoing, a prospective approach to
IPD meta-analysis can offer greater collective power to pro-
duce definitive results when, for example, it has not been
possible to adequately power individual trials for all the
outcomes of interest and/or there are practical or other bar-
riers to adhering to a single trial protocol. We also found a
prospective design being adopted, when sufficiently pow-
ered trials recruited less well than expected (Box 3, colon
cancer 1, Table 1), or the prognosis of the participants’
was more favorable than predicted at the design stage
(Box 3), such that events accrued more slowly than antici-
pated. In one example, these issues would have affected the
timely completion of the individual trials, reduced their po-
wer to detect effects of therapies reliably, and jeopardized
their continuation (Box 3). A prospective decision to pool
the trials has been used to encourage continued recruitment
into the individual trials and justify their ongoing follow-up
and funding (Box 3). A major advantage of prospective
meta-analysis is that hypotheses, inclusion criteria, and an-
alyses are defined before, and without influence from, the
results of individual trials, which is a potential source of
bias for retrospectively designed IPD meta-analyses [62].
Although individual trials often run according to their
own protocols and timetables, there is also the potential
for the proposed meta-analysis to directly influence the
day-to-day running of the individual studies. For example,
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we found that investigators may align trial materials and
procedures (stroke 1, preterm neonates 1, Table 1). A clear
challenge of this approach, however, is being able to
respond to the accumulating results of the individual trials,
and managing their impact on the remaining ongoing trials,
the meta-analysis collaboration, and subsequent meta-
analysis results.
3.2.2. Stopping ongoing trials
In a similar way to a standard systematic review, an IPD
meta-analysis that shows that an intervention is inferior to
standard treatment, or harmful, should discourage further
use of that intervention both in practice and in future trials.
Of course, a comprehensive IPD meta-analysis may show
this more definitively and reliably, or, importantly, for a
certain subgroup of participants (NSCLC 1, Table 1).
3.3. Impacts on trial analysis and interpretation
3.3.1. Informing the analyses
Prognostic factors or risk groups identified via IPD have
been used to adjust or stratify trial analyses (Box 2), as well
as being used to define the population to be studied in a new
trial. In addition, where an IPD meta-analysis has identified
participants or disease characteristics that seem to modify
treatment effects, this had led to further exploration and
testing in subsequent trials, for example, by stratifying
the analysis by these characteristics (Box 2).
3.3.2. Interpreting and reporting results
Trial results can be readily placed in the context of the
results of an existing meta-analysis using standard two-
stage techniques, and is possible both with aggregate data
[3,5] and IPD. The latter does not necessarily require access
to the full IPD, but rather the reported results of the IPD
meta-analysis. In fact, for the examples we identified, the
trial results were combined both with the results of an ex-
isting IPD meta-analysis and results of other trials pub-
lished subsequently, to provide the totality of evidence
about intervention effects. Anecdotal evidence also sug-
gests that participation in an IPD meta-analysis encourages
trialists to publish previously unreported trials or to publish
updated analyses.
3.4. Potential negative impacts on trials
As IPD meta-analyses can take years from inception to
final publication, awaiting the final results can delay the
start of a new trial by a similar time frame. Moreover, if
the results suggest benefit or harm of a particular interven-
tion, even if not definitively, this can jeopardize recruitment
to ongoing trials investigating that intervention.
4. Discussion
Through consultation with experts in the field, we have
identified a cohort of 29 examples of IPD meta-analyses
impacting directly on trials. They have influenced the selec-
tion of comparators and sample size calculations of subse-
quent trials, and also been used to place trial results in the
context of the other evidence in a similar fashion to aggre-
gate data reviews [4]. In addition, IPD meta-analyses have
played a role in the selection of participants, and in the
conduct, analysis, and interpretation of trials, particularly
in response to subgroup or prognostic factor analyses,
neither of which are not possible with aggregate data. This
study also highlights that IPD meta-analyses generate infor-
mation, for example, on the natural history of disease or on
the definition of outcomes that could be used to inform tri-
als, but we have yet to find evidence of this.
To our knowledge, this is the first attempt to explore how
IPD meta-analyses can impact on subsequent trials. By
considering relevant trial protocols, publications, and Web
sites, we have ensured that the examples presented here
are evidence based. That does not mean that the other
IPD meta-analyses we examined have not had an impact
on trials but rather that no evidence of this could be found.
Having targeted a selected group of individuals with expe-
rience in the conduct of IPD meta-analyses, many with
knowledge of related trials, means that the study represents
only a small subset of potential impacts. Indeed, many of
the examples are in the cancer and cardiovascular fields,
where there is a long history of using the IPD approach.
In other clinical areas, the collection of IPD for meta-
analysis has been a more recent phenomenon, and so, it
could be some time before any influence on trials becomes
apparent. Although our list of examples is illustrative rather
than exhaustive, it does emphasize potential missed oppor-
tunities to use retrospective or prospective IPD meta-
analysis in trial design, conduct, analysis, and
interpretation.
Those undertaking IPD meta-analyses might maximize
their impact on trials by publishing as speedily as possible,
following an open-access model, to ensurewidespread avail-
ability of results. Making full use of journal online facilities
and using reporting guidelines for systematic reviews based
on IPD [63] should ensure such reports are sufficiently
detailed and help trialists to select those IPD meta-analyses
that are well conducted [10]. The outputs and recommenda-
tions in IPD meta-analysis reports tend to be focused on
clinical practice, so perhaps there is a need to regard IPD
meta-analyses as playing an equally important role in inform-
ing subsequent clinical research. Structuring recommenda-
tions on the direction of new research around the quality of
the existing evidence, and the interventions, comparisons
and outcomes [63,64], would highlight gaps and areas for
improvement. Ideally, such recommendations would draw
on the spectrum of expertize found among trialists in an
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IPD collaborative group, whowill often be key players in the
next generation of trials. Furthermore, if these collaborations
could also be harnessed to plan and conduct future studies
more strategically, it might avoid the duplication of effort
and inadequately powered trials that remain a feature of some
areas of clinical research. Greater involvement of patients
and the public in IPDmeta-analyses [65] could provide extra
insight on which questions are important. Obviously, if the
results of an IPD meta-analysis are not definitive, research
recommendations should explicitly encourage recruitment
to existing relevant trials, so that their continuation is not
jeopardized.
Secondary analyses of the IPD, to address additional
clinical questions could be potentially very informative to
trialists, as well as making maximum use of the IPD
collected. Thus, making these a natural part of the process
would be desirable. Certainly, those conducting trials might
be able to help direct this kind of research by highlighting,
for example, that surrogate outcomes or potential prog-
nostic factors need evaluating. Also, where possible, IPD
meta-analysts should be amenable to requests for extra
information or analyses that might help trialists refine the
design and conduct of further trials.
Many trials do not appear to take prior trials [66] or sys-
tematic reviews [4] into account, so we encourage more
widespread use of evidence synthesis to inform all stages
of trials. Although we identified examples of IPD meta-
analyses having a direct impact on trials, sometimes in
ways not possible with aggregate data, the richness of the
results and the underlying data, and the collaborative ad-
vantages seem to be underused. The potential benefits of
both retrospective and prospective IPD meta-analyses to
clinical research need to be more widely recognized, espe-
cially as these projects are likely to benefit from a drive for
greater sharing of data held within trials [67]. Thus, wher-
ever available, well-conducted IPD meta-analyses should
be used to inform trials.
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